Acute Myeloid Leukemia Market, Industry Trends, Companies, Drugs and Analysis by DelveInsight

 Breaking News
  • No posts were found

Acute Myeloid Leukemia Market, Industry Trends, Companies, Drugs and Analysis by DelveInsight

December 14
22:18 2021
Acute Myeloid Leukemia Market, Industry Trends, Companies, Drugs and Analysis by DelveInsight
Acute Myeloid Leukemia Market
The Acute Myeloid Leukemia market is expected to grow positively during the forecast period (2018-2030)

DelveInsight’s Acute Myeloid Leukemia market report thoroughly explains the Acute Myeloid Leukemia, historical and forecasted epidemiology, as well as the Acute Myeloid Leukemia market trends in the 7MM. The report also proffers an analysis of the current Acute Myeloid Leukemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs.

Some of the Key Highlights from Acute Myeloid Leukemia Market Report

  • As per DelveInsight Acute Myeloid Leukemia epidemiology insights, the total incident cases was found to be 42,301 in the 7MM in 2020, of which the US accounted for the highest AML cases. 
  • In the United States, the highest Acute Myeloid Leukemia was among ≥75 age group in 2020.
  • Among EU5 countries, Spain had the lowest AML incidence cases in 2020.
  • Leading companies in the Acute Myeloid Leukemia market include Astex Pharmaceuticals, Chimerix, Takeda, Rafael Pharmaceutical, Delta-Fly Pharma, and others.
  • Key Acute Myeloid Leukemia therapies in the pipeline include ASTX727, Dociparstat Sodium, Pevonedistat, CPI-613, DFP-10917, and others.
  • ASTX727 is a one-of-a-kind fixed-dose combination of decitabine, the active ingredient in Dacogen, and E7727, a novel cytidine deaminase inhibitor (cedazuridine). ASTX727 is intended for the oral administration of decitabine.
  • The Acute Myeloid Leukemia market size was found to be USD 1251.1 million in 2020.

Have queries? Request for the sample @ Acute Myeloid Leukemia Market Research

Acute Myeloid Leukemia: Overview

Acute Myeloid Leukemia (AML), also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia, is a type of hematologic cancer characterized by clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and other tissues. AML can affect tissues other than bone marrow and blood, such as lymph nodes, the brain, skin, etc.

Acute Myeloid Leukemia Epidemiology Segmentation

The Acute Myeloid Leukemia report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Acute Myeloid Leukemia Total Diagnosed Cases 
  • Acute Myeloid Leukemia Gender-Specific Cases
  • Acute Myeloid Leukemia Age-Specific Cases 
  • Acute Myeloid Leukemia Genetic Mutation-Specific Cases 

Acute Myeloid Leukemia Treatment Landscape 

Most AML patients are treated with two chemotherapy (chemo) phases: remission induction (also known as induction) and consolidation (postremission therapy). APL is a subtype of AML that is treated differently. Because AML can progress rapidly, treatment should usually begin as soon as possible after diagnosis.

Acute Myeloid Leukemia Market Outlook

According to DelveInsight’s analysts, the market is expected to grow positively during the forecast period (2018–2030), owing primarily to increased incidence and the anticipated launch of novel therapies such as ASTX727 Dociparstat Sodium, Pevonedistat, CPI-613, and others.

Acute Myeloid Leukemia Pipeline Therapies and Key Companies 

  • ASTX727: Astex Pharmaceuticals
  • Dociparstat Sodium: Chimerix
  • Pevonedistat: Takeda
  • CPI-613: Rafael Pharmaceutical
  • DFP-10917: Delta-Fly Pharma

Learn more about the emerging therapies and companies @ Acute Myeloid Leukemia Pipeline Therapies

Table of Contents 

1.

Key Insights

2.

Report Introduction

3.

Acute Myeloid Leukemia (AML) Market Overview at a Glance

4.

Executive Summary of Acute Myeloid Leukemia (AML)

5.

Disease Background and Overview

6.

Epidemiology and Patient Population

7.

Organizations contributing towards Acute Myeloid Leukemia (AML)

8.

Case Reports

9.

Patient Journey

10.

Marketed Therapies

11.

Emerging Therapies

12.

Other Promising Therapies

13.

Acute Myeloid Leukemia (AML): 7 Major Market Analysis

14.

Market Drivers

15.

Market Barriers

16.

SWOT Analysis

17.

Unmet Needs

18.

Market Access

19.

KOL Views

20.

Appendix

21.

DelveInsight Capabilities

22.

Disclaimer

23.

About DelveInsight

Get in touch with our business executive for Healthcare Due Diligence Services

Related Reports

Chronic Phase Chronic Myeloid Leukemia Market

DelveInsight’s “Chronic Phase Chronic Myeloid Leukemia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Chronic Phase Chronic Myeloid Leukemia, historical and forecasted epidemiology, as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the 7MM.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/